Update on olaparib in ovarian cancer (Prof Ledermann - video) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, August 25, 2016

Update on olaparib in ovarian cancer (Prof Ledermann - video)


Published on Aug 2, 2016
Prof Ledermann talks to ecancertv at ASCO 2016 about the updated survival data associated with the PARP inhibitor olaparib in a certain subset of ovarian cancer patients.

He also highlights the novel exploratory endpoints that were used for the first time within an oncology trial (TFST and TSST), and highlights that 15% of patients entered into the study possessing mutant strains of BRCA are still receiving maintenance therapy 5 years later.

For future clinical use, it is important to establish precisely those patients who will benefit the most, due to the cost of the drug.


Post a Comment

Your comments?